Essential Role of the Anti-Inflammatory Cytokine IL-10 in the Fetal Regenerative Phenotype is Mediated Via Stat3 and Hyaluronan Synthase: Implications for Scarless Wound Healing

2012 ◽  
Vol 172 (2) ◽  
pp. 244
Author(s):  
A. Leung ◽  
S. Balaji ◽  
L. Le ◽  
N. Ghobril ◽  
F. Lim ◽  
...  
Keyword(s):  
Wound Healing ◽  
Inflammatory Cytokine ◽  
Essential Role ◽  
Hyaluronan Synthase ◽  
Anti Inflammatory ◽  
Anti Inflammatory Cytokine

scholarly journals Prototypical anti-inflammatory cytokine IL-10 prevents loss of IGF-I-induced myogenin protein expression caused by IL-1β

2008 ◽  
Vol 294 (4) ◽  
pp. E709-E718 ◽  
Author(s):  
Klemen Strle ◽  
Robert H. McCusker ◽  
Rodney W. Johnson ◽  
Samantha M. Zunich ◽  
Robert Dantzer ◽  
...  
Keyword(s):  
Inflammatory Cytokine ◽  
Muscle Wasting ◽  
Inflammatory Responses ◽  
Mapk Signaling ◽  
Protective Role ◽  
Igf I ◽  
Anti Inflammatory ◽  
Kinase Pathway ◽  
Anti Inflammatory Cytokine

Prolonged and excessive inflammation is implicated in resistance to the biological actions of IGF-I and contributes to the pathophysiology of neurodegenerative, metabolic, and muscle-wasting disorders. IL-10 is a critical anti-inflammatory cytokine that restrains inflammatory responses in macrophages and T cells by inhibiting cytokine and chemokine synthesis and reducing expression of their receptors. Here we demonstrate that IL-10 plays a protective role in nonhematopoietic cells by suppressing the ability of exogenous IL-1β to inhibit IGF-I-induced myogenin and myosin heavy chain expression in myoblasts. This action of IL-10 is not caused by impairment of IL-1β-induced synthesis of IL-6 or the ability of IL-1β to activate two members of the MAPK family, ERK1/2 and p38. Instead, this newly defined protective role of IL-10 occurs by specific reversal of IL-1β activation of the JNK kinase pathway. IL-10 blocks IL-1β-induced phosphorylation of JNK, but not ERK1/2 or p38, indicating that only the JNK component of the IL-1β-induced MAPK signaling pathway is targeted by IL-10. This conclusion is supported by the finding that a specific JNK inhibitor acts similarly to IL-10 to restore IGF-I-induced myogenin expression, which is suppressed by IL-1β. Collectively, these data demonstrate that IL-10 acts in a novel, nonclassical, protective manner in nonhematopoietic cells to inhibit the IL-1β receptor-induced JNK kinase pathway, resulting in prevention of IGF-I resistance.

Genetic susceptibility to Graves’ ophthalmopathy: The role of polymorphisms in anti-inflammatory cytokine genes

2010 ◽  
Vol 31 (4) ◽  
pp. 215-220 ◽  
Author(s):  
Omid Khalilzadeh ◽  
Mehdi Anvari ◽  
Alireza Esteghamati ◽  
Fatemeh Momen-Heravi ◽  
Armin Rashidi ◽  
...  
Keyword(s):  
Genetic Susceptibility ◽  
Inflammatory Cytokine ◽  
Cytokine Genes ◽  
Graves Ophthalmopathy ◽  
Anti Inflammatory ◽  
Anti Inflammatory Cytokine

Interleukin-19 as an Immunoregulatory Cytokine

2020 ◽  
Vol 14 (2) ◽  
pp. 191-199
Author(s):  
Yasuyuki Fujimoto ◽  
Nobuyuki Kuramoto ◽  
Masanori Yoneyama ◽  
Yasu-Taka Azuma
Keyword(s):  
T Cells ◽  
Inflammatory Cytokine ◽  
The Other ◽  
Acquired Immunity ◽  
Current Role ◽  
Immunoregulatory Cytokine ◽  
Anti Inflammatory ◽  
Anti Inflammatory Cytokine ◽  
Inflammatory Effect

IL-19 is a type of anti-inflammatory cytokine. Since the receptor for IL-19 is common to IL-20 and IL-24, it is important to clarify the role of each of the three cytokines. If three different cytokines bind to the same receptor, these three may have been produced to complement the other two. However, perhaps it is unlikely. Recently, the existence of a novel receptor for IL-19 was suggested. The distinction between the roles of the three cytokines still makes sense. On the other hand, because T cells do not produce IL-19, their role in acquired immunity is limited or indirect. It has been reported that IL-19 causes inflammation in some diseases but does not have an anti-inflammatory effect. In this review, we introduce the current role of IL-19 in each disease. In addition, we will describe the molecular mechanism of IL-19 and its development for the prevention of diseases. IL-19 was previously considered an anti-inflammatory cytokine, but we would like to propose it as an immunoregulatory cytokine.

scholarly journals The Role of the Anti-Inflammatory Cytokine Interleukin-10 in Tissue Fibrosis

2020 ◽  
Vol 9 (4) ◽  
pp. 184-198 ◽  
Author(s):  
Emily H. Steen ◽  
Xinyi Wang ◽  
Swathi Balaji ◽  
Manish J. Butte ◽  
Paul L. Bollyky ◽  
...  
Keyword(s):  
Inflammatory Cytokine ◽  
Interleukin 10 ◽  
Tissue Fibrosis ◽  
Anti Inflammatory ◽  
Anti Inflammatory Cytokine

Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout

2020 ◽  
Vol 79 (4) ◽  
pp. 536-544 ◽  
Author(s):  
Viola Klück ◽  
Rosanne C van Deuren ◽  
Giulio Cavalli ◽  
Amara Shaukat ◽  
Peer Arts ◽  
...  
Keyword(s):  
Inflammatory Cytokine ◽  
Rare Variants ◽  
Therapeutic Potential ◽  
Predictive Modelling ◽  
P Value ◽  
Functional Studies ◽  
Anti Inflammatory ◽  
Anti Inflammatory Cytokine

ObjectiveGout is characterised by severe interleukin (IL)-1-mediated joint inflammation induced by monosodium urate crystals. Since IL-37 is a pivotal anti-inflammatory cytokine suppressing the activity of IL-1, we conducted genetic and functional studies aimed at elucidating the role of IL-37 in the pathogenesis and treatment of gout.MethodsVariant identification was performed by DNA sequencing of all coding bases of IL37 using molecular inversion probe-based resequencing (discovery cohort: gout n=675, controls n=520) and TaqMan genotyping (validation cohort: gout n=2202, controls n=2295). Predictive modelling of the effects of rare variants on protein structure was followed by in vitro experiments evaluating the impact on protein function. Treatment with recombinant IL-37 was evaluated in vitro and in vivo in a mouse model of gout.ResultsWe identified four rare variants in IL37 in six of the discovery gout patients; p.(A144P), p.(G174Dfs*16), p.(C181*) and p.(N182S), whereas none emerged in healthy controls (Fisher’s exact p-value=0.043). All variants clustered in the functional domain of IL-37 in exon 5 (p-value=5.71×10−5). Predictive modelling and functional studies confirmed loss of anti-inflammatory functions and we substantiated the therapeutic potential of recombinant IL-37 in the treatment of gouty inflammation. Furthermore, the carrier status of p.(N182S)(rs752113534) was associated with increased risk (OR=1.81, p-value=0.031) of developing gout in hyperuricaemic individuals of Polynesian ancestry.ConclusionHere, we provide genetic as well as mechanistic evidence for the role of IL-37 in the pathogenesis of gout, and highlight the therapeutic potential of recombinant IL-37 for the treatment of gouty arthritis.

scholarly journals The Prognostic Determinant of Interleukin-10 in Patients with Acute Ischemic Stroke: An Analysis from the Perspective of Disease Management

2021 ◽  
Vol 2021 ◽  
pp. 1-9
Author(s):  
Wen Sun ◽  
Shuhui Wang ◽  
Shanji Nan
Keyword(s):  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Inflammatory Cytokine ◽  
Serum Levels ◽  
Interleukin 10 ◽  
Clinical Severity ◽  
Anti Inflammatory ◽  
Anti Inflammatory Cytokine

Background. In patients with ischemic stroke, the role of anti-inflammatory cytokine Interleukin-10 (IL-10) in predicting risk and outcomes is not very clear. This study is aimed at prospectively assessing the prognostic determinant value of IL-10 in patients with acute ischemic stroke in a cohort of Chinese people. Methods. In a prospective cohort study, consecutive first-ever patients with acute ischemic stroke admitted to our hospital were included from October 2019 to October 2020. The serum level of IL-10 was measured at baseline. A structured follow-up telephone interview was performed on day 90 after admission. Logistic regression analyses were used to assess the prognostic value of IL-10 to predict the poor functional outcome (defined as a modified Rankin Scale score of 3 to 6) and mortality. Results. The median age of the 236 enrolled patients was 65 years (interquartile range (IQR), 56-76), and 57.6% were male. There was a negative correlation between the National Institutes of Health Stroke Scale (NIHSS) score and IL-10 serum levels ( r   Spearman = − 0.221 , P = 0.001 ). Patients with elevated IL-10 levels (> the highest quartile = 5.24   pg / mL ; n = 79 ) were at significantly lower risk of poor functional outcomes (odds ratio (OR), 0.35; 95% confidence interval (CI), 0.19 to 0.63; P < 0.001 ) and mortality ( OR = 0.24 ; 95% CI = 0.11 –0.52; P < 0.001 ) compared with patients with IL-10 levels in the lowest three quartiles. Conclusions. Reduced serum levels of IL-10 were independently associated with both the clinical severity at admission and a poor functional prognosis in ischemic stroke patients, suggesting that the anti-inflammatory cytokine IL-10 was an important prognostic determinant.

Abstract 43: Renal Hemodynamic and Excretory Responses to Systemic Administration of Interleukin-10 in Anesthetized Mice

Hypertension ◽  
2013 ◽  
Vol 62 (suppl_1) ◽  
Author(s):  
Alexander Castillo ◽  
Dewan S Majid
Keyword(s):  
Receptor Antagonist ◽  
Inflammatory Cytokine ◽  
Interleukin 10 ◽  
Renal Tissue ◽  
Excretory Function ◽  
Anti Inflammatory ◽  
Renal Vascular ◽  
Renal Responses ◽  
Anti Inflammatory Cytokine

Recent studies have demonstrated that the anti-inflammatory cytokine, interleukin-10 (IL-10) is normally present in plasma and its protein is constitutively expressed in the renal tissue. However, the possible role of IL-10 in the regulation of renal hemodynamics and excretory function is not yet clearly defined. In the present study, we have examined the systemic and renal responses to intravenous administration of incremental doses of recombinant mouse IL-10 (0.015, 0.075 and 0.15 ng/min/g ; 45 min in each dose) in anesthetized mice (n=5). To determine the specificity of IL-10 actions, the responses to the middle dose were also assessed in the presence of its receptor antagonist, (mouse IL-10 Rα antibody; 1.5 ng/min/g; R&D system) in a separate group of mice (n=6). Standard clearance techniques were used to assess renal responses to infusions of IL-10 and its receptor antagonist. Renal blood flow (RBF) was determined by PAH clearances and glomerular filtration rate (GFR) was determined by inulin clearance. Infusion of IL-10 doses resulted in significant decreases in systemic mean arterial pressure (MAP; 98±1.9 to 89±3.9, 88±2.6 and 84±3.3 mmHg) and renal vascular resistance (RVR, 13.5±1.1 to 9.1±0.6, 7.1±0.5 and 7.1±0.5 mmHg/mL/min/g), increases in RBF (7.4±0.5 to 9.7±0.6, 10.6±0.5 and 9.8±0.6 mL/min/g) and GFR (1.06±0.05 to 1.45±0.13, 1.51±0.13 and 1.53±0.28 mL/min/g) without significant changes in urine flow (6.6±0.5 to 5.3±0.5, 5.5±1.1 and 5.3±1.1 μL/min/g ) or sodium excretion (0.58±0.08 to 0.52±0.18, 0.57±0.19 and 0.69±0.26 μmol/min/g). Administration of IL-10 receptor antagonist alone did not cause significant changes in MAP (90±3.7 to 89±5.3 mmHg), RVR (11.5±1.9 to 11.6±3.0 mmHg/mL/min/g), RBF (8.8±1.3 to 10.4±2.5 mL/min/g), GFR (1.06±0.08 to 1.20±0.19 mL/min/g) or other renal parameters. Infusion of the middle dose of IL-10 in the receptor antagonist pretreated mice failed to cause significant changes in RBF or GFR or other parameters confirming the specificity of its receptor activity in the mediation of observed renal responses to IL-10 infusion. These data suggest that the anti-inflammatory cytokine, IL-10 exerts vasodilator and hyper-filtration effects in the kidney but minimally influences the renal excretory function.

scholarly journals Role of anti-inflammatory cytokine IL-35 in the effects of sublingual immunotherapy

2018 ◽  
Vol 141 (2) ◽  
pp. AB278
Author(s):  
Hideaki Kouzaki ◽  
Atsushi Yuta ◽  
Masahiko Arikata ◽  
Takeshi Shimizu
Keyword(s):  
Inflammatory Cytokine ◽  
Sublingual Immunotherapy ◽  
Anti Inflammatory ◽  
Anti Inflammatory Cytokine
Sign in / Sign up

Export Citation Format

Share Document